-
Markets
-
Aktien
Sustainable finance2025 Euronext ESG Trends ReportWeiterlesenA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesWeiterlesenThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeWeiterlesenInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Funds
-
Fixed Income
European Defence BondsGroupe BPCE lists the first bondWeiterlesenFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Structured Products
-
Derivatives
Where European Government Bonds Meet the FutureFixed Income derivativesWeiterlesenTrade mini bond futures on main European government bonds
-
Rohstoffe
- Übersicht
- Kurse überblick
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Delivery & settlement
- Specifications & arrangements
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesWeiterlesenEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Resources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameWeiterlesenJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Genticel
Identification
Instrument name
GENTICEL
Symbol
GTCL
ISIN code
FR0011790542
Exchange / Market
Euronext
Trading location
Brussels
Paris
Products family
Stocks
Capitalization compartment
Compartment C
ICB
Biotechnology
Activity description
Genticel est spécialisé dans le développement de vaccins thérapeutiques destinés à la prévention du cancer du col de l’utérus chez les femmes infectées par le virus du papillome humain (HPV).
Source : Cofisem
Website address
http://www.genticel.com
Operation
IPO date
Fr. 04/04/2014
IPO type
Introduction par offre au public
IPO price
EUR 7.90
IPO type
Initial Public offering
Catégorie
IPO
Price range
EUR 6,75 - EUR 8,25
Capital raised
34,5